☆ 4.7 Article

Neurological symptoms and neuronal damage markers in acute COVID-19: Is there a correlation? A pilot study

JOURNAL OF MEDICAL VIROLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Immunology

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

Denise Battaglini et al.

Summary: This article summarizes the commonly used biomarkers in COVID-19, which play important roles in predicting disease severity, hospitalization, ICU admission, and mortality. It also discusses how novel analytical strategies can be applied in clinical practice, emphasizing the need for future research to focus on identifying a limited but essential number of laboratory biomarkers for predicting prognosis and outcomes in severe COVID-19.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Upper Respiratory Tract Levels of Severe Acute Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ Between Patients With Mild and Severe/Critical Coronavirus Disease 2019

Aylin Yilmaz et al.

Summary: The study found that viral RNA loads were highest early after symptom onset, and there was a moderate correlation between duration of symptoms and viral RNA shedding in patients with mild COVID-19.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Letter Clinical Neurology

COVID-19 impact on consecutive neurological patients admitted to the emergency department

Andrea Pilotto et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Add to Collection

Article Clinical Neurology

Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019

Raoul Sutter et al.

Summary: There is increasing evidence for various neurological manifestations of COVID-19, with higher sNfL concentrations observed in critically ill patients with COVID-19 compared to healthy controls and critically ill non-COVID-19 patients. Elevated sNfL levels were associated with unfavorable short-term outcomes, indicating common and pronounced neuronal injury in critically ill patients.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity

Johan Virhammar et al.

Summary: This study analyzed CSF biomarkers of CNS injury in 19 patients with neurological symptoms of COVID-19, finding elevated levels of NfL protein, GFAp, and total tau. NfL protein was found to be associated with central neurological symptoms and disease severity in these patients.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Editorial Material Clinical Neurology

Neurological infection with SARS-CoV-2-the story so far

Tom Solomon

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection

Article Immunology

Brain injury, endothelial injury and inflammatory markers are elevated and express sex-specific alterations after COVID-19

Jude Savarraj et al.

Summary: COVID-19 can cause brain and endothelial injury, with men showing higher levels of injury markers and inflammatory markers compared to women. Elevated levels of BIMs, CCs, and EIMs in COVID-19 patients suggest brain and endothelial injury, with men being more susceptible to risk factors than women.

JOURNAL OF NEUROINFLAMMATION (2021)

Add to Collection

Article Clinical Neurology

Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19

Anne Hege Aamodt et al.

Summary: Elevated concentrations of NfL and GFAp in COVID-19 patients upon admission may indicate increased mortality risk, and these biomarker concentrations are associated with clinical outcomes.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury

Erika Cione et al.

Summary: The multifunctional role of neuron-specific enolase (NSE) in lung diseases, particularly in COVID-19 patients, was explored in this study. Higher NSE levels were detected in COVID-19 patients compared to controls, and a significant increase in dyspnea severity was observed within the COVID-19 patient group. These findings suggest the potential for NSE as a clinical marker of disease progression in COVID-19.

PLOS ONE (2021)

Add to Collection

Article Immunology

Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?

Silvia Bozzetti et al.

Summary: The persistence of neurological symptoms and late axonal damage after SARS-CoV-2 infection is still unknown. The study found that a significant number of COVID-19 patients still experienced neurological symptoms during follow-up, with hyposmia, fatigue, myalgia, and impaired memory being the most common. Serum neurofilament light chain levels were not able to differentiate patients with or without persistent neurological symptoms, but there was a significant decrease in levels during follow-up. The study suggests that COVID-19 survivors do not show active axonal damage, which is a unique feature of acute SARS-CoV-2 infection.

IMMUNOLOGIC RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm

Maria A. Garcia et al.

Summary: The study found no obvious neuroinflammatory changes in the CSF of COVID-19 patients and no detection of SARS-CoV2 RNA, which does not support the neurovirulence of SARS-CoV2 or the role of neuroinflammation in the pathogenesis of neurological complications in COVID-19. Anti-SARS-CoV2 antibodies were present in the CSF of some critical COVID-19 patients, but the role of these antibodies and the mechanisms of neuronal damage remain unclear.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Cell Biology

Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19

Mercedes Prudencio et al.

Summary: Brain imaging studies of COVID-19 patients have shown evidence of neuroaxonal injury, and serum levels of neurofilament light chain (NFL) may predict the extent of neuronal damage and are associated with clinical outcomes. Lower NFL serum concentrations were observed in COVID-19 patients treated with remdesivir, suggesting that neuroaxonal injury should be considered as an outcome in acute pharmacotherapeutic trials for COVID-19.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up

Nelly Kanberg et al.

Summary: Plasma biomarkers of CNS injury were significantly elevated in severe COVID-19 cases during the acute phase but normalized after six months, indicating that neurological sequelae post COVID-19 are not associated with ongoing CNS injury. Despite this normalization, a considerable number of patients reported persistent neurological symptoms, suggesting that additional factors beyond CNS injury biomarkers may contribute to long-term neurological effects of COVID-19.

EBIOMEDICINE (2021)

Add to Collection

Review Clinical Neurology

Potential Neurologic Manifestations of COVID-19

Anna S. Nordvig et al.

Summary: Neurologic complications are increasingly recognized in the COVID-19 pandemic caused by SARS-CoV-2, with potential symptoms including headache, fatigue, dizziness, anosmia, ageusia, anorexia, myalgias, and more. Understanding the neurologic implications of COVID-19 can aid in recognizing and managing neurologic morbidity during and post the 2020 pandemic.

NEUROLOGY-CLINICAL PRACTICE (2021)

Add to Collection

Article Clinical Neurology

Evaluation of sleep-related respiratory disorders in patients with multiple sclerosis

Hikmet Sacmaci et al.

ACTA NEUROLOGICA BELGICA (2020)

Add to Collection

Review Clinical Neurology

Neurological Manifestations of COVID-19: A systematic review and current update

Abigail Whittaker et al.

ACTA NEUROLOGICA SCANDINAVICA (2020)

Add to Collection

Review Clinical Neurology

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019 A Review

Adeel S. Zubair et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Ling Mao et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID)

Carlo Ferrarese et al.

NEUROLOGICAL SCIENCES (2020)

Add to Collection

Letter Clinical Neurology

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19

Markus Ameres et al.

JOURNAL OF NEUROLOGY (2020)

Add to Collection

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Review Clinical Neurology

Neurological associations of COVID-19

Mark A. Ellul et al.

LANCET NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

Nelly Kanberg et al.

NEUROLOGY (2020)

Add to Collection

Article Neurosciences

The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier

Tetyana P. Buzhdygan et al.

NEUROBIOLOGY OF DISEASE (2020)

Add to Collection

Article Emergency Medicine

Cerebrospinal fluid findings and hypernatremia in COVID-19 patients with altered mental status

Hale Toklu et al.

INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE (2020)

Add to Collection

Letter Clinical Neurology

Potential neurological symptoms of COVID-19

Hai-Yang Wang et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

Federico Verde et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)

Add to Collection

Review Clinical Neurology

Neurofilaments as biomarkers in neurological disorders

Michael Khalil et al.

NATURE REVIEWS NEUROLOGY (2018)

Add to Collection

Review Neurosciences

New Insights into the Role of Neuron-Specific Enolase in Neuro-Inflammation, Neurodegeneration, and Neuroprotection

Azizul Haque et al.

BRAIN SCIENCES (2018)

Add to Collection

Review Clinical Neurology

Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain injury Dynamics: A Systematic Review

Eric Peter Thelin et al.

FRONTIERS IN NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

Neuron-specific enolase levels as a marker for possible neuronal damage in idiopathic intracranial hypertension

Yavuz Samanci et al.

ACTA NEUROLOGICA BELGICA (2017)

Add to Collection

Article Clinical Neurology

Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis

Giulio Disanto et al.

ANNALS OF NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Bob Olsson et al.

LANCET NEUROLOGY (2016)

Add to Collection

Review Clinical Neurology

Fluid biomarkers for mild traumatic brain injury and related conditions

Henrik Zetterberg et al.

NATURE REVIEWS NEUROLOGY (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.